The status of and future research into Myalgic Encephalomyelitis and Chronic Fatigue Syndrome: the need of accurate diagnosis, objective assessment, and acknowledging biological and clinical subgroups by Frank N. M. Twisk
PERSPECTIVE ARTICLE
published: 27 March 2014
doi: 10.3389/fphys.2014.00109
The status of and future research into Myalgic
Encephalomyelitis and Chronic Fatigue Syndrome: the
need of accurate diagnosis, objective assessment, and
acknowledging biological and clinical subgroups
Frank N. M. Twisk*
ME-de-Patiënten Foundation, Limmen, Netherlands
Edited by:
Niels H. Secher, University of
Copenhagen, Denmark
Reviewed by:





Frank N. M. Twisk, ME-de-Patiënten
Foundation, Zonnedauw 15, 1906
HB Limmen, Netherlands
e-mail: frank.twisk@hetnet.nl
Although Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS) are used
interchangeably, the diagnostic criteria define two distinct clinical entities. Cognitive
impairment, (muscle) weakness, circulatory disturbances, marked variability of symptoms,
and, above all, post-exertional malaise: a long-lasting increase of symptoms after a
minor exertion, are distinctive symptoms of ME. This latter phenomenon separates
ME, a neuro-immune illness, from chronic fatigue (syndrome), other disorders and
deconditioning. The introduction of the label, but more importantly the diagnostic criteria
for CFS have generated much confusion, mostly because chronic fatigue is a subjective
and ambiguous notion. CFS was redefined in 1994 into unexplained (persistent or
relapsing) chronic fatigue, accompanied by at least four out of eight symptoms, e.g.,
headaches and unrefreshing sleep. Most of the research into ME and/or CFS in the last
decades was based upon the multivalent CFS criteria, which define a heterogeneous
patient group. Due to the fact that fatigue and other symptoms are non-discriminative,
subjective experiences, research has been hampered. Various authors have questioned
the physiological nature of the symptoms and qualified ME/CFS as somatization.
However, various typical symptoms can be assessed objectively using standardized
methods. Despite subjective and unclear criteria and measures, research has observed
specific abnormalities in ME/CFS repetitively, e.g., immunological abnormalities, oxidative
and nitrosative stress, neurological anomalies, circulatory deficits and mitochondrial
dysfunction. However, to improve future research standards and patient care, it is crucial
that patients with post-exertional malaise (ME) and patients without this odd phenomenon
are acknowledged as separate clinical entities that the diagnosis of ME and CFS in
research and clinical practice is based upon accurate criteria and an objective assessment
of characteristic symptoms, as much as possible that well-defined clinical and biological
subgroups of ME and CFS patients are investigated in more detail, and that patients are
monitored before, during and after interventions with objective measures and biomarkers.
Keywords: Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, assessment, diagnosis, immune system,
post-exertional malaise, subgroups
INTRODUCTION
Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome
(CFS) have been marred by much controversy (Holgate et al.,
2011), from the authenticity of the symptoms (Chalder et al.,
1996; Carruthers et al., 2011) and the existence of the ME and
CFS as distinct clinical entities (Barsky and Borus, 1999; Twisk
and Arnoldus, 2013) to the etiology (Huibers and Wessely, 2006;
Carruthers et al., 2011), the pathophysiology (Vercoulen et al.,
1994; Maes and Twisk, 2010) and presumed effective interven-
tions, e.g., cognitive behavioral therapy (CBT) and graded exer-
cise therapies (GET) (Knoop et al., 2007; Twisk and Arnoldus,
2012).
An important part of the controversy originates from the
introduction of the label CFS, but even more from the defini-
tional criteria of this clinical entity (Fukuda et al., 1994), which
define a heterogeneous population of people of chronic fatigue
(Wilson et al., 2001), and the use of self-reported subjective mea-
sures for ambiguous and insignificant symptoms like “fatigue”
(Jason et al., 2009). The principle feature of CFS is (unexplained)
chronic fatigue (Fukuda et al., 1994).
ME, whether defined by the original criteria (Ramsay, 1988) or
the proposed new criteria (Carruthers et al., 2011), is not equiv-
alent to CFS (Fukuda et al., 1994), let alone a severe form of
incapacitating chronic fatigue (Sharpe et al., 1991; Reeves et al.,
2005). Distinctive symptoms of ME are profound (muscle) weak-
ness and cognitive deficits (“brain fog”). More importantly, ME
can be distinguished from other diseases, chronic fatigue and
deconditioning by post-exertional “malaise”: a prolonged inten-
sification of symptoms, e.g., “brain fog” and muscle pain after
a minor exertion. This distinctive phenomenon is reflected by a
www.frontiersin.org March 2014 | Volume 5 | Article 109 | 1
Twisk Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS)
dramatic fall in maximum oxygen uptake and oxygen uptake and
workload at the aerobic threshold at a second exercise test 24 h
after the first (Snell et al., 2013) and a long-lasting increase of
muscle metabolite-detecting receptors for pain and “fatigue” after
moderate exercise (White et al., 2012).
Methodological issues, e.g., symptom-based criteria, the sub-
jectivity of the symptoms, mixing patients with post-exertional
“malaise” and abnormalities (ME) and patients without this
phenomenon (CFS/not ME) in research and clinical practice,
and assessment of the clinical status and improvement thereof
in trials of proposed effective therapies using subjective mea-
sures, have yielded contradictory results and have fuelled the
debate.
Despite the heterogeneity of the patient population, due to the
equivocal CFS criteria, various abnormalities have been observed
repetitively in the CFS patient group as a whole or in substantial
subgroups of the CFS population. However, scientific progress has
been slow and unnecessarily obstructed by the methodological
obstacles mentioned above. In addition, due to the heterogeneity
of the patients studied selected by CFS criteria, it is highly unlikely
that future research will reveal one or more abnormalities that are
applicable to all CFS patients.
To surmount the impasse, which has lasted for decades, it is
essential to improve the standards of the research into ME/CFS,
it is crucial to leave the current methods behind us and to assess
symptoms objectively as much as possible, to make a clear distinc-
tion between patients with and without post-exertional abnor-
malities, e.g., by employing repeated cardiopulmonary exercise
tests, to accurately diagnose patients using ME and CFS criteria,
to define clinical and biological ME and CFS patient subgroups in
research studies, and to monitor patients before, during and after
trials using objective measures, however, trivial this may seem.
This partly due to the fact that, in contrast with other illnesses,
ME and CFS are not yet clearly defined by distinctive biomarkers.
Without doing so, the debate around ME/CFS will persist.
This article summarizes the current status and is directed
to the abnormalities established repeatedly and the potential
improvement of diagnosis of and research into ME and CFS.
CRITERIA
ME (1934)
Outbreaks of a disease resembling “atypical poliomyelitis”
(Gilliam, 1938) occurred from the 1940s through the 1980s at
various places over the world (The Medical Staff of The Royal
Free Hospital, 1957; 1978; Hyde et al., 1992). ME was identi-
fied as a new clinical entity in 1959 (Acheson, 1959) and has
been acknowledged as a disease of the central nervous sys-
tem/neurological disease by the World Health Organization since
1969 (WHO, 1967). The clinical picture was defined by Ramsay
and co-workers (Ramsay, 1988; Dowsett et al., 1990; Jason et al.,
2012a) in the 80 s. Distinctive symptoms of ME (Goodwin, 1981)
are: profound (muscle) weakness and tenderness, easy fatigability
of the muscles, neurological abnormalities, e.g., visual problems,
cognitive deficits (concentration and memory problems), circu-
latory disturbances, and post-exertional “malaise”: a (delayed)
long-lasting increase of symptoms after a minor physical and
mental exertion.
CFS (1994)
The diagnostic entity CFS was introduced in 1988 (Holmes et al.,
1988) after an outbreak in Nevada at Lake Tahoe in the mid-
eighties. CFS was redefined in 1994 (Fukuda et al., 1994) into
clinically evaluated, unexplained (persistent or relapsing) chronic
fatigue, accompanied by at least four out of a list of eight symp-
toms, e.g., sore throat, unrefreshing sleep, and headaches. The
majority of research intoME/CFS1 in the last two decades is based
upon these case criteria. Since “fatigue” and other symptoms, e.g.,
unrefreshing sleep, are subjective, non-specific and ambiguous,
the CFS criteria select a varied population of people with chronic
fatigue (Wilson et al., 2001).
ME (2011)
The heterogeneity of the CFS (Fukuda et al., 1994) patient pop-
ulation has impeded effective research and accurate diagnosis of
patients. For that reason a group of researchers have proposed cri-
teria (Carruthers et al., 2011) in order to distinguish ME from
CFS (Fukuda et al., 1994) and chronic fatigue (Sharpe et al.,
1991). According to this new criteria post-exertional “malaise” or
“neuro-immune exhaustion” (“a pathological inability to produce
sufficient energy on demand” resulting into symptom exacerba-
tion, e.g., flu-like symptoms and pain, after minor exertion) is
obligatory for the diagnosis ME. Post-exertional “malaise” should
be accompanied by specific neurological symptoms, impaired cel-
lular energy metabolism and/or transportation, and immune,
gastro-intestinal or genitourinary symptoms.
ME vs. CFS
AlthoughME and CFS are considered to be interchangeable labels
(WHO, 1992), criteria for ME (Carruthers et al., 2011) and CFS
(Fukuda et al., 1994) define distinct, partially overlapping clini-
cal entities (Twisk and Arnoldus, 2013). Post-exertional malaise
and cognitive deficits e.g., are not mandatory for the diagnosis
CFS, while these symptoms are obligatory for the diagnosis ME.
“Fatigue” is not obligatory to meet the diagnosis ME. The distinc-
tion between patients with ME/CFS with post-exertional malaise
and patients without post-exertional malaise is reflected by par-
ticular clinical and immunological differences (Maes et al., 2012a;
Brenu et al., 2013).
PREVALENCE AND IMPACT
Nacul et al. (2011) found that 0.19% of 143,000 individuals
(18–64 years) met the commonly used Fukuda criteria for CFS
(Fukuda et al., 1994), while 0.11% met the more strict criteria
for ME/CFS (Carruthers et al., 2003), including post-exertional
malaise. Prevalence rates of ME (Carruthers et al., 2011) remain
to be investigated, but based upon (Nacul et al., 2011; Jason et al.,
2012b; Maes et al., 2012a; Brenu et al., 2013) it is estimated that
30–50% of the subjects meeting the CFS (Fukuda et al., 1994)
criteria fulfill the more stringent criteria for ME (Carruthers
et al., 2011). Patients experience significantly more impairment
than patients with hypertension, congestive heart failure, type II
diabetes mellitus, acute myocardial infarction, multiple sclero-
sis and depression (Komaroff et al., 1996). The ME/CFS criteria
1ME/CFS refers to ME and/or CFS.
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(Carruthers et al., 2003) select patients with more disability and
more physical, mental and cognitive symptoms than patients with
the diagnosis CFS (Fukuda et al., 1994) not meeting these criteria
(Jason et al., 2012b).
DIAGNOSIS
Nowadays, the diagnoses ME and CFS are often based upon sub-
jective measures reported by patients, e.g., fatigue (Chalder et al.,
1993; Vercoulen et al., 1994) and physical functioning (Ware and
Sherbourne, 1992; McHorney et al., 1993). However, to bypass
problems created by ambiguous symptom-based criteria, e.g.,
heterogeneity of the patient population, a clinical assessment ME
of CFS and its severity should be based upon objective measures
as much as possible. Several distinctive symptoms can be assessed
objectively (see Table 1).
Symptoms that cannot be assessed objectively easily due to
their nature, are: “fatigue”, widespread muscle and/or joint pain,
often amplified after a (minor) exertion, hypersensitivity to light,
sound, odor and chemicals, e.g., anaesthetics (likely due to “cen-
tral sensitization”), thermoregulation problems and “sickness
behavior.” Research (Jason et al., 2014) has shown that minimum
frequency and severity thresholds should be used for self-reported
symptoms to reduce the likelihood of misclassification.
ABNORMALITIES
The heterogeneity of the patient population (Whistler et al., 2003)
and the use of various methods and samples have contributed
to conflicting results. Despite this various specific abnormalities
have been observed repetitively in theME/CFS patient population
or substantial subgroup thereof (Table 2).
Various of the abnormalities mentioned in Table 2 are
reflected by deviant gene expression (Kaushik et al., 2005;
Whistler et al., 2005; Fuite et al., 2008; Gow et al., 2009).
Aberrations at the cellular level include mitochondrial dys-
function (Booth et al., 2012), inflammation, immunosuppres-
sion, e.g., reduced Natural Killer cell lytic activity (Hardcastle
et al., 2014), immune dysfunction, e.g., increased synthesis of
(Th2-associated) cytokines (Fletcher et al., 2009), increased pro-
duction of inducible nitric oxide (NO) synthase by peripheral
lymphocytes (Maes et al., 2007b). Tissue anomalies encompass
significantly low oxygen uptake by muscle cells (Vermeulen and
Vermeulen van Eck, 2014), increased intramuscular acidosis after
maximal voluntary contraction with significantly prolonged pH
recovery times (Jones et al., 2012), an inverse correlation between
increased skeletal muscle pH and reduced cerebral blood flow
at rest and during dynamic stimulation (He et al., 2013), and
differential expression of genes with key roles in mitochondrial
function and oxidative balance in the vastus lateralis muscle
(Pietrangelo et al., 2009). Neurological abnormalities in ME/CFS
patients or subgroups thereof include reduced gray and white
brain matter (Puri et al., 2012), increased magnetic resonance
imaging (MRI) abnormalities, mainly T2 signal hyperintensities
in the frontal lobes (Lange et al., 1999), significant reductions
in cerebral blood flow across various brain regions (Yoshiuchi
et al., 2006), spinal fluid abnormalities (Natelson et al., 2005) and
increased ventricular lactate (Shungu et al., 2012).
Since many of the research studies which observed aberra-
tions in ME/CFS compared patients with sedentary controls, the
abnormalities cannot be attributed to deconditioning. Whether
the nameME is appropriate or not remains subject of debate (Van
der Meer and Lloyd, 2012), but various findings in ME/CFS actu-
ally indicate muscular and neurological abnormalities. However,
immunological abnormalities, antigens, increased oxidative and
nitrosative stress, and gastro-intestinal dysfunction seem to be
at the core of the etiology of ME/CFS (Maes and Twisk, 2010).
The distinction between patients meeting the proposed criteria
for ME (Carruthers et al., 2011) and patients with CFS (Fukuda
et al., 1994) not fulfilling these criteria is reflected by specific
immunological abnormalities (Brenu et al., 2013).
Exercise and orthostatic stress seems to induce or intensify
(long lasting) abnormalities in patient subgroups, e.g., a sig-
nificant decrease of the oxygen consumption and workload at
exhaustion and at the ventilatory (anaerobic) threshold at a sec-
ond exercise test 24 h later (Snell et al., 2013); a long-term increase
of messenger RNA (mRNA) of metabolite-detecting receptors
after sustained moderate exercise (White et al., 2012); a signifi-
cant prolongation of the time taken for pH to recover to baseline
after exercise (Jones et al., 2012); reduced prefrontal oxygenation
during exercise and recovery when compared to healthy con-
trols similar in physical activity levels (Patrick Neary et al., 2008);
impaired cognitive functioning 24 h after physically demanding
exercise compared with sedentary healthy individuals (LaManca
et al., 1998); and an substantially higher increase in NO metabo-
lites in relation to workload during exercise (Suárez et al., 2010).
Although the exact etiological mechanisms remains to be elu-
cidated, the post-exertional malaise phenomenon could arguably
be explained by the observation that physical stress, particu-
larly anaerobic exercise, can intensify pre-existing abnormalities:
inflammation (Fisher-Wellman and Bloomer, 2009; Mogharnas
et al., 2011; Sakharov et al., 2012), immunosuppression (Millard
et al., 2013), immune dysfunction (Steensberg et al., 2001), oxida-
tive and nitrosative stress (Bloomer et al., 2005; Fisher-Wellman
and Bloomer, 2009; Sakharov et al., 2012) and hyperpermeabil-
ity of the intestines (Lambert, 2009; Lamprecht and Frauwallner,
2012). Since the anaerobic threshold is already low in ME/CFS
patients or subgroups (De Becker et al., 2000; Vermeulen et al.,
2010), the effects of exercise programmes should be monitored
objectively and continuously, e.g., by using CPET.
SUBGROUPS
CLINICAL SUBGROUPS
In addition to a breakdown into patients with post-exertional
malaise (ME) and without this hallmark feature (CFS/not ME),
a subdivision into subgroups based upon onset (sudden/viral? or
gradual), type and severity of symptoms, gender, age, duration
and/or comorbidities seems inevitable to unravel common and
distinct deviant biological pathways in more detail. Potentially
relevant clinical subdivisions are summarized in Table S1 (see
Supplementary Material).
BIOLOGICAL SUBGROUPS
Several studies have revealed distinct biological ME/CFS patient
subgroups, often associated with distinct differences in the clinical
picture as illustrated in Table S2 (Supplementary Material). The
most relevant subdivisions are based upon (exercise-induced)
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Table 1 | Symptoms and tests.
Symptom Test References
Loss of energy/weakness Cardiopulmonary exercise test (CPET) (American
College of Sports Medicine, 2009; Balady et al.,
2010)
De Becker et al., 2000; Farquhar et al., 2002; Jones
et al., 2012
Cognitive deficits Specific neurocognitive tests* (Wechsler, 1981;
Cambridge Cognition, 1999; Lezak et al., 2004;
Strauss et al., 2006)
DeLuca et al., 1993, 2004; Tiersky et al., 1997;
Dickson et al., 2009; Thomas and Smith, 2009;
Cockshell and Mathias, 2010; Constant et al., 2011
Muscle weakness Muscle (power and endurance) tests (Van der
Ploeg, 1991; Andrews et al., 1996; Wang et al.,
2002; Stark et al., 2011)
Paul et al., 1999; Fulcher and White, 2000; Lawrie
et al., 2000; Siemionow et al., 2004
Orthostatic intolerance Tilt table test (Streeten, 1987; American College of
Cardiology et al., 1996; Task Force for the
Diagnosis and Management of Syncope, 2009)
Rowe et al., 1995; De Lorenzo et al., 1997;
Streeten and Anderson, 1998; Stewart et al., 1999;
Newton et al., 2007; Galland et al., 2008; Hoad
et al., 2008; Katz et al., 2011
Post-exertional malaise
Physical Repeated cardiopulmonary exercise tests, 24 h
apart (Katch et al., 1982; Amann et al., 2004;
Bensimhon et al., 2008; Balady et al., 2010)
VanNess et al., 2006; Patrick Neary et al., 2008;
Vermeulen et al., 2010; Snell et al., 2013
Cognitive Specific neurocognitive tests* (Wechsler, 1981;
Cambridge Cognition, 1999; Lezak et al., 2004;
Strauss et al., 2006), before and after a CPET or
orthostatic stress
VanNess et al., 2007; Ocon et al., 2012
Visual symptoms Useful field of view tests (Ball et al., 1993; Ball and
Owsley, 1993) and eye movement tests
(Rommelse et al., 2008)
Leslie, 1997; Vedelago, 1997; Badham and
Hutchinson, 2013; Hutchinson and Badham, 2013
Sleep disturbances Polysomnografic investigation (Rechtschaffen and
Kales, 1968; Dumermuth et al., 1983; Lo et al.,
2002; Iber et al., 2007)
Kishi et al., 2008, 2011; Decker et al., 2009
Defective stress response Hormonal investigation (Kirschbaum et al., 1993;
Holtorf, 2008; Kovacs and Ojeda, 2011; Melmed
et al., 2011)
MacHale et al., 1998; Gaab et al., 2002; Cleare,
2004; Jerjes et al., 2005; Holtorf, 2008;
Torres-Harding et al., 2008; Jammes et al., 2009;
Papadopoulos and Cleare, 2011; Tak et al., 2011
*Cognitive impairments can be identified if appropriate measures/tests are used (Thomas and Smith, 2009; Cockshell and Mathias, 2010).
immunological abnormalities. Acknowledging immunological,
infectious and endocrine subdivisions seem to be crucial to estab-
lish the efficacy and safety of pharmacological and behavioral
therapies. In addition to differential gene expression genes in all
patients, upregulation and downregulation of specific genes are
likely to reflect specific (biological and clinical) ME/CFS patient
subgroups.
DISCUSSION
Although ME and CFS are considered to be equivalents (WHO,
1992), the diagnostic criteria for ME (Ramsay, 1988; Dowsett
et al., 1990; Carruthers et al., 2011; Jason et al., 2012a) and
CFS (Sharpe et al., 1991; Fukuda et al., 1994; Reeves et al.,
2005) define distinct clinical, partly overlapping, entities. CFS
criteria focus primarily on chronic fatigue, which, due to is
nature, is a subjective and ambiguous criterion (Jason et al., 2010,
2011a; Davenport et al., 2011). ME is principally characterized
by neurocognitive impairment, (muscle) weakness and sleep dis-
turbances, but the distinctive feature of ME is post-exertional
“malaise”: a (long-lasting) aggravation of symptoms, e.g., pain,
“brain fog” and weakness, after a minor physical or mental
exertion (Carruthers et al., 2011; Maes et al., 2012a).
The question whether the label ME is appropriate (Baraniuk
et al., 2005; Schutzer et al., 2011) or not remains to be established,
but considering the confusion due to the introduction of chronic
fatigue as the principle criterion and the use of symptom-based
criteria and questionnaires in clinical practice and research, it
seems crucial to assess various characteristic symptoms objec-
tively and to make a clear distinction between patients with post-
exertional malaise (ME) and patients without post-exertional
malaise. Objective tests, e.g., repeated exercise tests (CPETs) and
tilt table testing, could be employed as a solid basis for the diagno-
sis, the validation, adjustment and refinement of ME (Carruthers
et al., 2011) and CFS (Fukuda et al., 1994) criteria and the
definition of clinical ME and CFS patients subgroups in research.
Trials intotheefficacyandsafetyofpharmacological(Flugeetal.,
2011;Wattetal., 2012)andbehavioral therapies, e.g.,CBTandGET
(Knoop et al., 2007; Heins et al., 2010; White et al., 2011), should
employ objective measures of the clinical status and improvement
thereof and biomarkers to establish the effects of these therapies
in specific clinical and biological subgroups (Kindlon, 2012).
To unravel the enigma and to resolve the controversy, patients
should be monitored before, during and after potentially effective
therapies in research and clinical practice using objectivemeasures
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Table 2 | Abnormalities in ME/CFS.
Abnormality References
Immunological aberrations (inflammation, immune activation,
immunosuppression and immune dysfunction);
Klimas et al., 1990; Fletcher et al., 2009; Lorusso et al., 2009;
Meeus et al., 2009; Brenu et al., 2011; Maes et al., 2012b
consistent with processes observed during (latent) infection; Lloyd et al., 1993; Kerr et al., 2008a; Broderick et al., 2010
Intestinal dysbiosis, inflammation and hyperpermeability, Maes et al., 2007a; Sheedy et al., 2009; Lakhan and Kirchgessner,
2010; De Meirleir et al., 2013; Frémont et al., 2013
associated with systemic immune system abnormalities; Maes et al., 2012c; Groeger et al., 2013
(reactivating and/or persistent) infections; Hilgers and Frank, 1996; Chia and Chia, 2003; Nicolson et al., 2003;
Chia et al., 2010; Chapenko et al., 2012
Elevated oxidative and nitrosative stress; Zhang et al., 1995; Kennedy et al., 2010; Maes and Twisk, 2010;
Tomic et al., 2012
Mitochondrial dysfunction and damage to mitochondria; Behan et al., 1991; Pietrangelo et al., 2009; Booth et al., 2012;
Meeus et al., 2013
Hypovolemia, diminished cardiac output and Streeten and Bell, 1998; Hurwitz et al., 2009; Miwa and Fujita, 2009;
Hollingsworth et al., 2012
blood and oxygen supply deficits to muscles and brain, McCully and Natelson, 1999; Biswal et al., 2011; Ocon, 2013
especially in an upright position and during exercise; LaManca et al., 1999; Peckerman et al., 2003; Wyller et al., 2007;
Patrick Neary et al., 2008
Reduced (maximum) oxygen uptake; Farquhar et al., 2002; Weinstein et al., 2009; Vermeulen et al., 2010;
Jones et al., 2012
Neurological abnormalities; Lange et al., 2005; Chen et al., 2008; Puri et al., 2012; Natelson,
2013
Hypocortisolism/blunted hypothalamic-pituitary-adrenal (HPA) axis
response;
Demitrack et al., 1991; Lorusso et al., 2009; Papadopoulos and
Cleare, 2011; Tak et al., 2011
Ion channel dysfunction (channelopathy); Watson et al., 1997; Whistler et al., 2005; Broderick et al., 2006;
Cameron et al., 2007
A deviant physiological responses to exertion Thambirajah et al., 2008; Jones et al., 2012; Light et al., 2012; Smylie
et al., 2013; Snell et al., 2013
(Kindlon, 2012), e.g., oxygen uptake at the anaerobic threshold
and maximum oxygen uptake (VO2max), and biomarkers, e.g.,
(exercise-induced) cytokine levels.
CONCLUSION
Looking at the definitional criteria of ME, e.g., (muscle)
weakness, cognitive impairment, but above all post-exertional
“malaise,” ME is not equivalent to CFS, let alone chronic fatigue.
The introduction of the label CFS, but more importantly a
fatigue-based case definition, have resulted into research of a het-
erogeneous patient population of patients with chronic fatigue.
Combined with the use of subjective measures this has created
confusion and controversy.
Several authors have questioned the validity and nature of
symptoms reported by patients. This debate can be resolved by
assessing characteristic symptoms using objective methods, if
possible, e.g., repeated exercise tests, cognitive tests, orthostatic
testing and visual tests.
Despite the ambiguous CFS criteria and methods applied,
researchers have observed various specific abnormalities repeat-
edly, e.g., (reactivating or chronic) infections, immunological
anomalies (inflammation, immune activation and dysfunction),
and long lasting deviant effects of exercise, in the ME/CFS patient
population or substantial subgroups thereof.
However, in order to advance in research and clinical practice,
to unravel the enigmatic cause(s) of ME and CFS and to develop
effective therapies, it seems crucial (a) that patients with post-
exertional “malaise” (ME) and “CFS” patients without post-
exertional phenomena are acknowledged as two separate clinical
and research entities; (b) that typical symptoms of ME and CFS
are assessed objectively as much as possible; (c) that well-defined
clinical subgroups of ME and CFS, e.g., patients with ortho-
static intolerance or patients with sudden-onset, are investigated
in more detail; (d) that biomarkers, e.g., immunological status
in rest and after exertion, are used to distinguish biological sub-
types in research; and (e) that trials into the efficacy of therapies
use objective measures of the clinical status and biomarkers to
establish the effects of these therapies in ME or CFS patients
or subgroups thereof impartially, e.g., by a (positive) change in
the oxygen uptake at the anaerobic threshold and cognitive tests
scores.
Considering the central role of post-exertional and cogni-
tive impairment (“brain fog”) in ME/CFS, interesting areas of
research include exercise-induced abnormalities, e.g., immune
responses, oxidative and nitrosative stress, oxygen uptake, mito-
chondrial dysfunction, and brain energetics before, during and
after exercise and cognitive stimulation (Quistorff et al., 2008;
Bergersen and Gjedde, 2012; Shungu et al., 2012).
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SUPPLEMENTARY MATERIAL
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